Lifeboat Foundation

One of the oldest known molecules, the ribosome, creates proteins based on a copy of the genetic code found in the genome, known as mRNA. Scientists have believed that the ribosome performed the same type of work with all mRNA, like a standardized assembly line that it did not regulate on its own. However, researchers from the University of Copenhagen have discovered this is not the case.

Their findings are published in the journal Developmental Cell in an article entitled “Ribosomal RNA 2′-O-methylation dynamics impact cell fate decisions.”

“It has long been known that there are different types of ribosomes. But it has been assumed that no matter what mRNA you give the ribosome, it will produce a protein. But our results suggest that different types of ribosomes produce specific proteins,” says Anders H. Lund, professor at the Biotech Research and Innovation Center at the University of Copenhagen.

Recombinant adeno-associated virus (rAAV) vectors are a cornerstone of genetic medicine. These hollow virus particles are used to deliver commercial gene therapies like Glybera and Luxturna, as well as many other candidates still in development.

Despite this, the biopharmaceutical industry has yet to find the most effective way of making rAAV vectors at scale. McKinsey analysts recently described vector production as one of the major challenges faced by gene therapy developers. And the situation is only going to get worse as the gene therapy market evolves and begins developing products for larger patient populations.

“With a shift beyond ultra-rare indications, viral-vector manufacturing requires rapid expansion to be able to address various diseases in the commercial space,” the analysts wrote, adding, “The broader application of viral vector-based gene therapies (for example, to more common diseases) requires higher yields and lower cost of goods (COGs).”

A new artificial intelligence model can predict people’s risk of multiple sclerosis years before diagnosis, potentially enabling quicker treatment, according to research revealed at the 2023 AACC Annual Scientific Meeting & Clinical Lab Expo. Another breaking study demonstrates how machine learning can help detect lab samples contaminated with intravenous fluids—a finding that could reduce lab errors that delay diagnosis and raise healthcare costs.

Taken together, the results highlight key advances in the use of artificial intelligence and machine learning to improve patient care.

AI model harnesses patient data to predict multiple sclerosis risk.

Dr. James East explains what causes Barrett’s esophagus, who is at risk, how it’s diagnosed and treated, and how you can reduce your risk of developing the condition.

Imagine you could take a medicine that prevents the decline that come with age and keeps you healthy. Scientists are trying to find a drug that has these effects. The current most promising anti-ageing drug is Rapamycin, known for its positive effects on life and health span in experimental studies with laboratory animals. To obtain the maximum beneficial effects of the drug, it is often given lifelong. However, even at the low doses used in prevention for age-related decline, negative side effects may occur, and it is always desirable to use the lowest effective dose. A research group at the Max Planck Institute for Biology of Ageing in Cologne, Germany, has now shown in laboratory animals that brief exposure to rapamycin has the same positive effects as lifelong treatment opening new doors for a potential application in humans.

Combatting the negative effects of ageing is increasingly becoming the focus of research scientists. Lifestyle changes can improve health of older people, but alone is not sufficient to prevent the ills of older age. Repurposing existing drugs for ‘geroprotection’ is providing an additional weapon in the prevention of age-related decline. The current most promising anti-ageing drug is rapamycin, a cell growth inhibitor and immunosuppressant that is normally used in cancer therapy and after organ transplantations. “At the doses used clinically, rapamycin can have undesirable side-effects, but for the use of the drug in the prevention of age-related decline, these need to be absent or minimal. Therefore, we wanted to find out when and how long we need to give rapamycin in order to achieve the same effects as lifelong treatment”, explains Dr. Paula Juricic, the leading investigator of the study in the department of Prof.

Cognitive dysfunction in aging is a major biomedical challenge. Whether treatment with klotho, a longevity factor, could enhance cognition in human-relevant models such as in nonhuman primates is unknown and represents a major knowledge gap in the path to therapeutics. We validated the rhesus form of the klotho protein in mice showing it increased synaptic plasticity and cognition. We then found that a single administration of low-dose, but not high-dose, klotho enhanced memory in aged nonhuman primates. Systemic low-dose klotho treatment may prove therapeutic in aging humans.

In people with the variant, past exposure to other coronaviruses may prep the immune system to fight off the disease.

NIH-funded clinical trial finds cholesterol-lowering treatment reduced cardiovascular events by 35%.

A National Institute of Health-supported study found that statins, a class of cholesterol-lowering medications, may offset the high risk of cardiovascular disease in people living with HIV by more than a third, potentially preventing one in five major cardiovascular events or premature deaths in this population. People living with HIV can have a 50–100% increased risk for cardiovascular disease. The findings are published in the New England Journal of Medicine.

This is a good use of AI. Definitely regular it but I can see it’s contributing to medical research.

Summary: Researchers have utilized artificial intelligence to uncover the promising potential of extra virgin olive oil (EVOO) in combating Alzheimer’s disease (AD).

By integrating AI, chemistry, and omics research, the study identified specific bioactive compounds in EVOO that could contribute to the treatment and prevention of AD. Ten phytochemicals within EVOO, such as quercetin, genistein, luteolin, and kaempferol, were found to exhibit potential impacts on AD protein networks.

Continue reading “AI Unlocks Olive Oil’s Potential in Alzheimer’s Battle” »